{"transactions":[{"id":729192,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T20:54:06.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":5176,"derivative":{"exercise_price":70.79,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":5176},"source":{"system":"sec-edgar","filing":"0001193125-26-279690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526279690/ownership.xml","form_type":"4"}},{"id":881344,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-25T22:00:05.000Z","date":"2026-02-24","kind":"sale","planned":false,"acquired":false,"shares":13515,"price":14.47,"value":195562.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":390803,"source":{"system":"sec-edgar","filing":"0001193125-26-072001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000119312526072001/ownership.xml","form_type":"4"}},{"id":887443,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-23T22:00:03.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":16381,"price":13.62,"value":223109.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":404318,"source":{"system":"sec-edgar","filing":"0001193125-26-064254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000119312526064254/ownership.xml","form_type":"4"}},{"id":892518,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T22:00:08.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":828000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":828000,"derivative":{"exercise_price":12.44,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":828000},"source":{"system":"sec-edgar","filing":"0001193125-26-059639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000119312526059639/ownership.xml","form_type":"4"}},{"id":957862,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-29T22:00:04.000Z","date":"2025-12-23","kind":"sale","planned":false,"acquired":false,"shares":9922,"price":10.01,"value":99319.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":420699,"source":{"system":"sec-edgar","filing":"0001193125-25-335482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000119312525335482/ownership.xml","form_type":"4"}},{"id":1086621,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T21:56:09.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over three years, with one-third vesting on July 14, 2026 and the remainder vesting in substantially equal monthly installments over the following two years."}],"balance_after":20000,"derivative":{"exercise_price":57.74,"expiration_date":"2035-07-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-096357","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025096357/ownership.xml","form_type":"4"}},{"id":1240080,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-27T22:00:07.000Z","date":"2025-02-25","kind":"sale","planned":false,"acquired":false,"shares":12529,"price":8.53,"value":106872.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":430621,"source":{"system":"sec-edgar","filing":"0000950170-25-029199","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017025029199/ownership.xml","form_type":"4"}},{"id":1252177,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-21T23:00:06.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":360000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":360000,"derivative":{"exercise_price":9.43,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":360000},"source":{"system":"sec-edgar","filing":"0000950170-25-025029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017025025029/ownership.xml","form_type":"4"}},{"id":1252176,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-21T23:00:06.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":443150,"source":{"system":"sec-edgar","filing":"0000950170-25-025029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017025025029/ownership.xml","form_type":"4"}},{"id":1320856,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-27T23:00:04.000Z","date":"2024-12-24","kind":"sale","planned":false,"acquired":false,"shares":8400,"price":11.87,"value":99708.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":263150,"source":{"system":"sec-edgar","filing":"0000950170-24-140856","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017024140856/ownership.xml","form_type":"4"}},{"id":1621673,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T22:00:22.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":320000,"derivative":{"exercise_price":17.54,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0000950170-24-019462","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017024019462/ownership.xml","form_type":"4"}},{"id":1621672,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-23T22:00:22.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":271550,"source":{"system":"sec-edgar","filing":"0000950170-24-019462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017024019462/ownership.xml","form_type":"4"}},{"id":1699279,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-27T23:30:07.000Z","date":"2023-12-26","kind":"sale","planned":false,"acquired":false,"shares":4272,"price":9.24,"value":39473.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":111550,"source":{"system":"sec-edgar","filing":"0000950170-23-073405","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017023073405/ownership.xml","form_type":"4"}},{"id":1841782,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-29T20:59:59.000Z","date":"2023-06-28","kind":"sale","planned":false,"acquired":false,"shares":759,"price":11.4,"value":8652.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":115822,"source":{"system":"sec-edgar","filing":"0000950170-23-030805","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017023030805/ownership.xml","form_type":"4"}},{"id":1879370,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-05-24T20:36:47.000Z","date":"2023-05-23","kind":"sale","planned":false,"acquired":false,"shares":707,"price":9.15,"value":6469.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":116581,"source":{"system":"sec-edgar","filing":"0000950170-23-023939","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017023023939/ownership.xml","form_type":"4"}},{"id":1913158,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-04-26T20:23:44.000Z","date":"2023-04-25","kind":"sale","planned":false,"acquired":false,"shares":716,"price":10.59,"value":7582.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":117288,"source":{"system":"sec-edgar","filing":"0000950170-23-014838","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000095017023014838/ownership.xml","form_type":"4"}},{"id":1937610,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-27T20:05:10.000Z","date":"2023-03-23","kind":"sale","planned":false,"acquired":false,"shares":706,"price":10.51,"value":7420.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":118004,"source":{"system":"sec-edgar","filing":"0000899243-23-009714","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924323009714/doc4.xml","form_type":"4"}},{"id":1995183,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-23T22:06:39.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":211000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":211000,"derivative":{"exercise_price":11.03,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":211000},"source":{"system":"sec-edgar","filing":"0000899243-23-006004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924323006004/doc4.xml","form_type":"4"}},{"id":1995182,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-23T22:06:39.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":118710,"source":{"system":"sec-edgar","filing":"0000899243-23-006004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924323006004/doc4.xml","form_type":"4"}},{"id":2213876,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-05T22:04:27.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":1620,"price":10.9,"value":17658.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the \"ESPP\"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022."}],"balance_after":9710,"source":{"system":"sec-edgar","filing":"0000899243-22-025077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924322025077/doc4.xml","form_type":"4"}},{"id":2239840,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-07T20:33:16.000Z","date":"2022-06-06","kind":"purchase","acquired":true,"shares":8090,"price":12.4,"value":100316.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.34 to $12.45. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8090,"source":{"system":"sec-edgar","filing":"0000899243-22-021346","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924322021346/doc4.xml","form_type":"4"}},{"id":2347074,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Stock Unit","published_at":"2022-03-08T02:50:52.000Z","date":"2022-03-05","kind":"grant","acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. The performance stock units vest upon the Issuer's common stock achieving a specified price per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer. The performance stock units vest upon the Issuer's common stock achieving a specified price per share."}],"balance_after":215000,"derivative":{"expiration_date":"2025-03-05","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0000899243-22-009841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924322009841/doc4.xml","form_type":"4"}},{"id":2537891,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-20T20:35:10.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":2710000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 2,710,000 shares of the Issuer's Common Stock, which shall vest on a pro-rated basis commencing on October 18, 2021, with 1/48 of the shares vesting on a monthly basis over four years, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":2710000,"derivative":{"exercise_price":21.12,"expiration_date":"2031-10-17","underlying":"Common Stock","underlying_shares":2710000},"source":{"system":"sec-edgar","filing":"0000899243-21-040774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731193/000089924321040774/doc4.xml","form_type":"4"}},{"id":382330,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2021-01-06T01:13:37.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":14946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award."}],"balance_after":0,"derivative":{"expiration_date":"2020-12-31","underlying":"Common Stock, $0.10 par value","underlying_shares":14946},"source":{"system":"sec-edgar","filing":"0000014272-21-000028","document":"wf-form4_160989560418282.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427221000028/wf-form4_160989560418282.xml","form_type":"4"}},{"id":382329,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2021-01-06T01:13:37.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":7660,"price":62.03,"value":475149.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld for payment of taxes upon vesting of awards."}],"balance_after":38889,"source":{"system":"sec-edgar","filing":"0000014272-21-000028","document":"wf-form4_160989560418282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427221000028/wf-form4_160989560418282.xml","form_type":"4"}},{"id":382328,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2021-01-06T01:13:37.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":14946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award."}],"balance_after":46549,"source":{"system":"sec-edgar","filing":"0000014272-21-000028","document":"wf-form4_160989560418282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427221000028/wf-form4_160989560418282.xml","form_type":"4"}},{"id":383319,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-12-04T01:24:23.000Z","date":"2020-12-02","kind":"exercise","acquired":false,"shares":6594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock unit vests in four equal annual installments beginning on December 2, 2020."}],"balance_after":19782,"derivative":{"expiration_date":"2023-12-02","underlying":"Common Stock, $0.10 par value","underlying_shares":6594},"source":{"system":"sec-edgar","filing":"0000014272-20-000298","document":"wf-form4_160704504862220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000298/wf-form4_160704504862220.xml","form_type":"4"}},{"id":383318,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-12-04T01:24:23.000Z","date":"2020-12-02","kind":"tax_withholding","acquired":false,"shares":3380,"price":62.18,"value":210168.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld for payment of taxes upon vesting of awards."}],"balance_after":31603,"source":{"system":"sec-edgar","filing":"0000014272-20-000298","document":"wf-form4_160704504862220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000298/wf-form4_160704504862220.xml","form_type":"4"}},{"id":383317,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-12-04T01:24:23.000Z","date":"2020-12-02","kind":"exercise","acquired":true,"shares":6594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in four equal annual installments beginning on December 2, 2020."}],"balance_after":34983,"source":{"system":"sec-edgar","filing":"0000014272-20-000298","document":"wf-form4_160704504862220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000298/wf-form4_160704504862220.xml","form_type":"4"}},{"id":384458,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-11-03T21:28:51.000Z","date":"2020-10-30","kind":"exercise","acquired":false,"shares":4650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock unit vests in three equal annual installments beginning on October 30, 2018."}],"balance_after":0,"derivative":{"expiration_date":"2020-10-30","underlying":"Common Stock, $0.10 par value","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000014272-20-000275","document":"wf-form4_160443891475377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000275/wf-form4_160443891475377.xml","form_type":"4"}},{"id":384457,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-11-03T21:28:51.000Z","date":"2020-10-30","kind":"tax_withholding","acquired":false,"shares":2291,"price":58.45,"value":133908.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld for payment of taxes upon vesting of awards."}],"balance_after":28389,"source":{"system":"sec-edgar","filing":"0000014272-20-000275","document":"wf-form4_160443891475377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000275/wf-form4_160443891475377.xml","form_type":"4"}},{"id":384456,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-11-03T21:28:51.000Z","date":"2020-10-30","kind":"exercise","acquired":true,"shares":4650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal annual installments beginning on October 30, 2018."}],"balance_after":30680,"source":{"system":"sec-edgar","filing":"0000014272-20-000275","document":"wf-form4_160443891475377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000275/wf-form4_160443891475377.xml","form_type":"4"}},{"id":391215,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-05-05T20:49:24.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":2908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on May 1, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on May 1, 2018."}],"balance_after":0,"derivative":{"expiration_date":"2020-05-01","underlying":"Common Stock, $0.10 par value","underlying_shares":2908},"source":{"system":"sec-edgar","filing":"0000014272-20-000162","document":"wf-form4_158871174702049.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000162/wf-form4_158871174702049.xml","form_type":"4"}},{"id":391214,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-05-05T20:49:24.000Z","date":"2020-05-01","kind":"tax_withholding","acquired":false,"shares":1433,"price":60.26,"value":86352.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld for payment of taxes upon vesting of awards."}],"balance_after":26030,"source":{"system":"sec-edgar","filing":"0000014272-20-000162","document":"wf-form4_158871174702049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000162/wf-form4_158871174702049.xml","form_type":"4"}},{"id":391213,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-05-05T20:49:24.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":2908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on May 1, 2018."}],"balance_after":27463,"source":{"system":"sec-edgar","filing":"0000014272-20-000162","document":"wf-form4_158871174702049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000162/wf-form4_158871174702049.xml","form_type":"4"}},{"id":393442,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Performance Shares","published_at":"2020-03-12T22:10:51.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":32082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2023."}],"balance_after":32082,"derivative":{"expiration_date":"2023-03-10","underlying":"Common Stock, $0.10 par value","underlying_shares":32082},"source":{"system":"sec-edgar","filing":"0000014272-20-000112","document":"wf-form4_158405103353946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000112/wf-form4_158405103353946.xml","form_type":"4"}},{"id":393441,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and President, Hematology"}}],"security":"Market Share Units","published_at":"2020-03-12T22:10:51.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":21388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date."}],"balance_after":21388,"derivative":{"expiration_date":"2024-03-10","underlying":"Common Stock, $0.10 par value","underlying_shares":21388},"source":{"system":"sec-edgar","filing":"0000014272-20-000112","document":"wf-form4_158405103353946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000112/wf-form4_158405103353946.xml","form_type":"4"}},{"id":394040,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-03-04T01:04:25.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":17204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on March 1, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on March 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on March 1, 2020."}],"balance_after":34410,"derivative":{"expiration_date":"2022-03-01","underlying":"Common Stock, $0.10 par value","underlying_shares":17204},"source":{"system":"sec-edgar","filing":"0000014272-20-000088","document":"wf-form4_158328384746829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000088/wf-form4_158328384746829.xml","form_type":"4"}},{"id":394039,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-03-04T01:04:25.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":8473,"price":59.06,"value":500415.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld for payment of taxes upon vesting of restricted stock units awards."}],"balance_after":24555,"source":{"system":"sec-edgar","filing":"0000014272-20-000088","document":"wf-form4_158328384746829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000088/wf-form4_158328384746829.xml","form_type":"4"}},{"id":394038,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-03-04T01:04:25.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":17204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on March 1, 2020."}],"balance_after":33028,"source":{"system":"sec-edgar","filing":"0000014272-20-000088","document":"wf-form4_158328384746829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000088/wf-form4_158328384746829.xml","form_type":"4"}},{"id":395898,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-02-07T01:48:51.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":2076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on February 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on February 4, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on February 4, 2020."}],"balance_after":4152,"derivative":{"expiration_date":"2022-02-04","underlying":"Common Stock, $0.10 par value","underlying_shares":2076},"source":{"system":"sec-edgar","filing":"0000014272-20-000078","document":"wf-form4_158104011239112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000078/wf-form4_158104011239112.xml","form_type":"4"}},{"id":395897,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-02-07T01:48:51.000Z","date":"2020-02-04","kind":"tax_withholding","acquired":false,"shares":1071,"price":64.29,"value":68854.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld for payment of taxes upon vesting of awards."}],"balance_after":15824,"source":{"system":"sec-edgar","filing":"0000014272-20-000078","document":"wf-form4_158104011239112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000078/wf-form4_158104011239112.xml","form_type":"4"}},{"id":395896,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2020-02-07T01:48:51.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":2076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock unit vests in three equal installments beginning on February 4, 2020."}],"balance_after":16895,"source":{"system":"sec-edgar","filing":"0000014272-20-000078","document":"wf-form4_158104011239112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000078/wf-form4_158104011239112.xml","form_type":"4"}},{"id":397495,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-01-04T01:37:18.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":33183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award."}],"balance_after":33183,"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock, $0.10 par value","underlying_shares":33183},"source":{"system":"sec-edgar","filing":"0000014272-20-000034","document":"wf-form4a_157810181956331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000034/wf-form4a_157810181956331.xml","form_type":"4/A","original_submission_date":"2019-11-27"}},{"id":397494,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2020-01-04T01:37:18.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":14946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( \"CVR\") per share or, with respect to equity awards (in some cases), per share underlying each such equity award (\"Merger Consideration\"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration (\"FDA\") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award."}],"balance_after":14946,"derivative":{"expiration_date":"2020-12-31","underlying":"Common Stock, $0.10 par value","underlying_shares":14946},"source":{"system":"sec-edgar","filing":"0000014272-20-000034","document":"wf-form4a_157810181956331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427220000034/wf-form4a_157810181956331.xml","form_type":"4/A","original_submission_date":"2019-11-27"}},{"id":398319,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-12-04T21:58:20.000Z","date":"2019-12-02","kind":"grant","acquired":true,"shares":26376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on December 2, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal annual installments beginning on December 2, 2020."}],"balance_after":26376,"derivative":{"expiration_date":"2023-12-02","underlying":"Common Stock, $0.10 par value","underlying_shares":26376},"source":{"system":"sec-edgar","filing":"0000014272-19-000238","document":"wf-form4_157549668296245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000238/wf-form4_157549668296245.xml","form_type":"4"}},{"id":398558,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:44.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":33182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award."}],"balance_after":33182,"derivative":{"expiration_date":"2022-03-01","underlying":"Common Stock, $0.10 par value","underlying_shares":33182},"source":{"system":"sec-edgar","filing":"0000014272-19-000213","document":"wf-form4_157489387998406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000213/wf-form4_157489387998406.xml","form_type":"4"}},{"id":398557,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:44.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":51614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The restricted stock unit vests in three equal annual installments beginning on March 1, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock unit vests in three equal annual installments beginning on March 1, 2020."}],"balance_after":51614,"derivative":{"expiration_date":"2022-03-01","underlying":"Common Stock, $0.10 par value","underlying_shares":51614},"source":{"system":"sec-edgar","filing":"0000014272-19-000213","document":"wf-form4_157489387998406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000213/wf-form4_157489387998406.xml","form_type":"4"}},{"id":398556,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:44.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":6228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The restricted stock unit vests in three equal annual installments beginning on February 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock unit vests in three equal annual installments beginning on February 4, 2020."}],"balance_after":6228,"derivative":{"expiration_date":"2022-02-04","underlying":"Common Stock, $0.10 par value","underlying_shares":6228},"source":{"system":"sec-edgar","filing":"0000014272-19-000213","document":"wf-form4_157489387998406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000213/wf-form4_157489387998406.xml","form_type":"4"}},{"id":398555,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:44.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 8, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 8, 2019."}],"balance_after":9965,"derivative":{"expiration_date":"2021-05-08","underlying":"Common Stock, $0.10 par value","underlying_shares":9965},"source":{"system":"sec-edgar","filing":"0000014272-19-000213","document":"wf-form4_157489387998406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000213/wf-form4_157489387998406.xml","form_type":"4"}},{"id":398554,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:44.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":14945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award."}],"balance_after":14945,"derivative":{"expiration_date":"2021-03-01","underlying":"Common Stock, $0.10 par value","underlying_shares":14945},"source":{"system":"sec-edgar","filing":"0000014272-19-000213","document":"wf-form4_157489387998406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000213/wf-form4_157489387998406.xml","form_type":"4"}},{"id":398553,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:44.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":4650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The restricted stock unit vests in three equal annual installments beginning on October 30, 2018."},{"field":"date","element":"transactionDate","label":"F3","text":"On November 20, 2019 (\"Closing Date\"), Bristol-Myers Squibb Company (\"BMS\") completed the previously announced acquisition of Celgene Corporation (\"Celgene\") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), and Celgene.  Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the \"Merger\"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock unit vests in three equal annual installments beginning on October 30, 2018."}],"balance_after":4650,"derivative":{"expiration_date":"2020-10-30","underlying":"Common Stock, $0.10 par value","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000014272-19-000213","document":"wf-form4_157489387998406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000213/wf-form4_157489387998406.xml","form_type":"4"}},{"id":398590,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Restricted Stock Units","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":2908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 1, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each restricted stock unit converts into one share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock unit vests in three equal annual installments beginning on May 1, 2018."}],"balance_after":2908,"derivative":{"expiration_date":"2020-05-01","underlying":"Common Stock, $0.10 par value","underlying_shares":2908},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398589,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":19621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":19621,"derivative":{"exercise_price":38.41,"expiration_date":"2028-10-29","underlying":"Common Stock, $0.10 par value","underlying_shares":19621},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398588,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":19619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":19619,"derivative":{"exercise_price":47.81,"expiration_date":"2028-07-30","underlying":"Common Stock, $0.10 par value","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398587,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":19619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":19619,"derivative":{"exercise_price":44.7,"expiration_date":"2028-05-08","underlying":"Common Stock, $0.10 par value","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398586,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9299,"derivative":{"exercise_price":55.52,"expiration_date":"2028-01-29","underlying":"Common Stock, $0.10 par value","underlying_shares":9299},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398585,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9300,"derivative":{"exercise_price":54.29,"expiration_date":"2027-10-30","underlying":"Common Stock, $0.10 par value","underlying_shares":9300},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398584,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":5843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":5843,"derivative":{"exercise_price":72.42,"expiration_date":"2027-07-31","underlying":"Common Stock, $0.10 par value","underlying_shares":5843},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398583,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":5843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":5843,"derivative":{"exercise_price":66.35,"expiration_date":"2027-05-01","underlying":"Common Stock, $0.10 par value","underlying_shares":5843},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398582,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":12272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":12272,"derivative":{"exercise_price":60.53,"expiration_date":"2027-01-30","underlying":"Common Stock, $0.10 par value","underlying_shares":12272},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398581,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":12205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":12205,"derivative":{"exercise_price":54.94,"expiration_date":"2026-10-31","underlying":"Common Stock, $0.10 par value","underlying_shares":12205},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398580,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":5843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":5843,"derivative":{"exercise_price":61.34,"expiration_date":"2026-08-01","underlying":"Common Stock, $0.10 par value","underlying_shares":5843},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398579,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":5812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":5812,"derivative":{"exercise_price":56.44,"expiration_date":"2026-05-02","underlying":"Common Stock, $0.10 par value","underlying_shares":5812},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398578,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9299,"derivative":{"exercise_price":54.2,"expiration_date":"2026-02-01","underlying":"Common Stock, $0.10 par value","underlying_shares":9299},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398577,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9350,"derivative":{"exercise_price":61.01,"expiration_date":"2025-11-09","underlying":"Common Stock, $0.10 par value","underlying_shares":9350},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398576,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9350,"derivative":{"exercise_price":70.89,"expiration_date":"2025-07-27","underlying":"Common Stock, $0.10 par value","underlying_shares":9350},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398575,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9350,"derivative":{"exercise_price":58.78,"expiration_date":"2025-05-04","underlying":"Common Stock, $0.10 par value","underlying_shares":9350},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398574,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":7012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":7012,"derivative":{"exercise_price":63.41,"expiration_date":"2025-02-02","underlying":"Common Stock, $0.10 par value","underlying_shares":7012},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398573,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9350,"derivative":{"exercise_price":62.67,"expiration_date":"2024-12-19","underlying":"Common Stock, $0.10 par value","underlying_shares":9350},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398572,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":6975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":6975,"derivative":{"exercise_price":55.44,"expiration_date":"2024-10-27","underlying":"Common Stock, $0.10 par value","underlying_shares":6975},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398571,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":13949,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":13949,"derivative":{"exercise_price":47.12,"expiration_date":"2024-07-28","underlying":"Common Stock, $0.10 par value","underlying_shares":13949},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398570,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":6974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":6974,"derivative":{"exercise_price":39.95,"expiration_date":"2024-02-03","underlying":"Common Stock, $0.10 par value","underlying_shares":6974},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398569,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":7440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":7440,"derivative":{"exercise_price":43.85,"expiration_date":"2023-12-02","underlying":"Common Stock, $0.10 par value","underlying_shares":7440},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398568,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":6975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":6975,"derivative":{"exercise_price":42,"expiration_date":"2023-10-28","underlying":"Common Stock, $0.10 par value","underlying_shares":6975},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398567,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":6975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":6975,"derivative":{"exercise_price":38.35,"expiration_date":"2023-07-29","underlying":"Common Stock, $0.10 par value","underlying_shares":6975},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398566,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":6974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":6974,"derivative":{"exercise_price":31.85,"expiration_date":"2023-04-29","underlying":"Common Stock, $0.10 par value","underlying_shares":6974},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398565,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":10463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":10463,"derivative":{"exercise_price":26.6,"expiration_date":"2023-01-28","underlying":"Common Stock, $0.10 par value","underlying_shares":10463},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398564,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":16740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":16740,"derivative":{"exercise_price":21.63,"expiration_date":"2022-12-17","underlying":"Common Stock, $0.10 par value","underlying_shares":16740},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398563,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":10464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":10464,"derivative":{"exercise_price":19.72,"expiration_date":"2022-10-31","underlying":"Common Stock, $0.10 par value","underlying_shares":10464},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398562,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":10460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":10460,"derivative":{"exercise_price":19.61,"expiration_date":"2022-04-30","underlying":"Common Stock, $0.10 par value","underlying_shares":10460},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398561,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Option (right to buy)","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":3255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":3255,"derivative":{"exercise_price":19.55,"expiration_date":"2022-01-30","underlying":"Common Stock, $0.10 par value","underlying_shares":3255},"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398560,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":1966,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"401(k)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Based on a plan statement as of the end of the most recent fiscal quarter."}],"balance_after":1966,"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":398559,"issuer":{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Hematology"}}],"security":"Common Stock, $0.10 par value","published_at":"2019-11-27T22:31:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":14819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 20, 2019 (\"Closing Date\"), Bristol-Myers Squibb Company (\"BMS\") completed the previously announced acquisition of Celgene Corporation (\"Celgene\") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), and Celgene.  Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the \"Merger\"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( \"CVR\") per share or, with respect to equity awards (in some cases), per share underlying each such equity award (\"Merger Consideration\"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration (\"FDA\") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee."}],"balance_after":14819,"source":{"system":"sec-edgar","filing":"0000014272-19-000212","document":"wf-form4_157489385725608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000001427219000212/wf-form4_157489385725608.xml","form_type":"4"}},{"id":3362108,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":27749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":27749},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362107,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3348},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362106,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":5357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5357},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362105,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362104,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362103,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":71.43,"expiration_date":"2028-10-29","underlying":"Common Stock","underlying_shares":10549},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362102,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":88.91,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":10548},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362101,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":83.13,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":10548},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362100,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.26,"expiration_date":"2028-01-29","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362099,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.97,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362098,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":135.41,"expiration_date":"2027-07-31","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362097,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":124.06,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362096,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:43.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":113.18,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":6563},"source":{"system":"sec-edgar","filing":"0001415889-19-001381","document":"form4-11222019_071130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001381/form4-11222019_071130.xml","form_type":"4"}},{"id":3362304,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:39.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":102.18,"expiration_date":"2026-10-31","underlying":"Common Stock","underlying_shares":6562},"source":{"system":"sec-edgar","filing":"0001415889-19-001380","document":"form4-11222019_071126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001380/form4-11222019_071126.xml","form_type":"4"}},{"id":3362303,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:39.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.69,"expiration_date":"2026-08-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001380","document":"form4-11222019_071126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001380/form4-11222019_071126.xml","form_type":"4"}},{"id":3362302,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":15727,"kind":"person","name":"AHMED NADIM","position":1,"cik":"0001731193","reported_name":"AHMED NADIM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL HEM. AND ONC."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:39.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":104.97,"expiration_date":"2026-05-02","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001380","document":"form4-11222019_071126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001380/form4-11222019_071126.xml","form_type":"4"}}],"next_cursor":"2019-11-22T07:31:39.000000Z,3362302"}